Abstract Library

#4190 Burden of medication in patients with lung neuroendocrine tumors (NETs) in a US real-world setting

Introduction: Real-world evidence on patients with lung NETs, specifically on comorbidities and the prevalence of carcinoid syndrome (CS), is lacking.

Conference:

Presenting Author:

Authors: Starr J, Houchard A, Pommie C, Ribeiro-Oliveira Jr A, Chan J,

Keywords: lung, neuroendocrine tumor, concomitant medication, costs,

#4134 Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumors in the lungNENomics project

Introduction: The lungNENomics project analysed 300 lung neuroendocrine tumors (NETs), of which 259 cases were pathologically reviewed by six expert pathologists.

Conference:

Presenting Author: Mathian E

Authors: Mathian E, Drouet Y, Sexton-Oates A, Papotti M, Pelosi G,

Keywords: Lung neuroendocrine neoplasm, Pathology, Deep-learning, Ki-67, PHH3,

#4015 Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)

Introduction: Angiogenesis plays a key role in development and progression of NENs and synergism has been observed when combined with immune-checkpoint inhibitors in other tumors.

Conference:

Presenting Author: Molina-Cerrillo J

Authors: Molina-Cerrillo J, Grande E, Benavent M, Garcia-Carbonero R, Teule A,

Keywords: neuroendocrine neoplasm, Cabozantinib, Atezolizumab, CABATEN, prospective multi-cohort Basket Phase II Trial,

#4013 A phase 3 randomised study of 177Lu-edotreotide or everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (LEVEL, GETNE-T2217)

Introduction: Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SSTR)-positive lung neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: García-Álvarez A, Garcia-Carbonero R, Anido U, Jimenez-Fonseca P, Del Olmo-García M,

Keywords: Lung NET, Peptide receptor radionuclide therapy,

#3937 Gender differences in lung neuroendocrine tumors: A single center experience

Introduction: Lung neuroendocrine tumors (L-NET) are the second most common NET. No consistent data are available about gender difference due to their low prevalence.

Conference:

Presenting Author:

Authors: Liccardi A, Minotta R, Cannavale G, Benevento E, Di Iasi G,

Keywords: Lung neuroendocrine tumor, gendere differences, survival, risk factors, carcinoid tumor,